NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $10.36 -0.47 (-4.34%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.18▼$10.9650-Day Range$8.32▼$11.0052-Week Range$1.76▼$13.17Volume1.73 million shsAverage Volume3.59 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$13.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcutis Biotherapeutics alerts: Email Address Arcutis Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside28.7% Upside$13.33 Price TargetShort InterestBearish20.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 10 Articles This WeekInsider TradingSelling Shares$360,910 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.56) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.20 out of 5 starsMedical Sector721st out of 910 stocksPharmaceutical Preparations Industry340th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.56% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 8.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 2.4 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arcutis Biotherapeutics this week, compared to 5 articles on an average week.Search Interest13 people have searched for ARQT on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $360,910.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Arcutis Biotherapeutics is held by insiders.Read more about Arcutis Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.56) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 6.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesSeptember 6 at 9:12 AM | insidertrades.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells $107,700.00 in StockAugust 22, 2024 | insidertrades.comPatrick Burnett Sells 1,728 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 7 at 12:51 AM | nasdaq.comArcutis Biotherapeutics Rings the Opening BellSeptember 6 at 3:15 AM | finance.yahoo.comInsider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)September 5 at 10:15 PM | msn.comArcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 5 at 4:00 PM | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest UpdateSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 2, 2024 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Moderate Buy" by AnalystsAugust 30, 2024 | markets.businessinsider.comArcutis Reports Positive Results For Integument Study Of Roflumilast Cream 0.05% In AD In ChildrenAugust 30, 2024 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Now Covered by Jefferies Financial GroupAugust 29, 2024 | msn.comJefferies Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy RecommendationAugust 28, 2024 | markets.businessinsider.comBuy Rating Initiated on Arcutis Biotherapeutics Amidst Zoryve’s Market Expansion and Promising Sales TrajectoryAugust 28, 2024 | benzinga.comAssessing Arcutis Biotherapeutics: Insights From 4 Financial AnalystsAugust 22, 2024 | seekingalpha.comArcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks LikelyAugust 22, 2024 | globenewswire.comArcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 16, 2024 | finance.yahoo.comQ2 2024 Arcutis Biotherapeutics Inc Earnings CallSee More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Stock Price Target$13.33 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+28.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-150.51% Pretax Margin-147.90% Return on Equity-145.41% Return on Assets-51.04% Debt Debt-to-Equity Ratio1.09 Current Ratio8.46 Quick Ratio8.19 Sales & Book Value Annual Sales$132.06 million Price / Sales9.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book6.52Miscellaneous Outstanding Shares115,764,000Free Float104,766,000Market Cap$1.20 billion OptionableOptionable Beta1.18 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Comp: $60.83kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Comp: $722.94kMr. L. Todd Edwards (Age 60)Senior VP & Chief Commercial Officer Comp: $755.64kMr. David J. Topper (Age 66)Senior VP & Chief Financial Officer Mr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Mr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Comp: $626.22kMs. Amanda SheldonHead of Corporate CommunicationsMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVAOcular TherapeutixNASDAQ:OCULPhathom PharmaceuticalsNASDAQ:PHATORIC PharmaceuticalsNASDAQ:ORICKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInsiders & InstitutionsHoward G WelgusSold 10,000 sharesTotal: $107,700.00 ($10.77/share)Patrick BurnettSold 1,728 sharesTotal: $14,325.12 ($8.29/share)Perceptive Advisors LLCBought 808,500 shares on 8/16/2024Ownership: 1.346%Capital Impact Advisors LLCBought 65,147 shares on 8/16/2024Ownership: 0.056%Algert Global LLCBought 10,415 shares on 8/16/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $3.23 at the beginning of the year. Since then, ARQT stock has increased by 220.7% and is now trading at $10.36. View the best growth stocks for 2024 here. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.06. The firm earned $30.86 million during the quarter, compared to analyst estimates of $31 million. Arcutis Biotherapeutics had a negative net margin of 150.51% and a negative trailing twelve-month return on equity of 145.41%. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Top institutional investors of Arcutis Biotherapeutics include Rubric Capital Management LP (8.48%), Ensign Peak Advisors Inc (1.84%), Perceptive Advisors LLC (1.35%) and Candriam S.C.A. (1.13%). Insiders that own company stock include Life Sciences Viii L Frazier, Orbimed Advisors Llc, Todd Franklin Watanabe, David W Osborne, Patrick Burnett, Howard G Welgus, Masaru Matsuda, Larry Todd Edwards, Patricia A Turney and Scott L Burrows. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX) and BioNTech (BNTX). This page (NASDAQ:ARQT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts